These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 8557348

  • 21. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae.
    Hui GS, Gosnell WL, Case SE, Hashiro C, Nikaido C, Hashimoto A, Kaslow DC.
    J Immunol; 1994 Sep 15; 153(6):2544-53. PubMed ID: 8077664
    [Abstract] [Full Text] [Related]

  • 22. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria.
    Siddiqui WA, Tam LQ, Kramer KJ, Hui GS, Case SE, Yamaga KM, Chang SP, Chan EB, Kan SC.
    Proc Natl Acad Sci U S A; 1987 May 15; 84(9):3014-8. PubMed ID: 3554251
    [Abstract] [Full Text] [Related]

  • 23. In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.
    Pang AL, Hashimoto CN, Tam LQ, Meng ZQ, Hui GS, Ho WK.
    Infect Immun; 2002 Jun 15; 70(6):2772-9. PubMed ID: 12010962
    [Abstract] [Full Text] [Related]

  • 24. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria.
    Perera KL, Handunnetti SM, Holm I, Longacre S, Mendis K.
    Infect Immun; 1998 Apr 15; 66(4):1500-6. PubMed ID: 9529073
    [Abstract] [Full Text] [Related]

  • 25. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD, Saleh S, Kovacevic S, Wang L, Black CG, Plebanski M, Coppel RL.
    Malar J; 2011 Sep 16; 10():266. PubMed ID: 21920045
    [Abstract] [Full Text] [Related]

  • 26. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.
    Woehlbier U, Epp C, Kauth CW, Lutz R, Long CA, Coulibaly B, Kouyaté B, Arevalo-Herrera M, Herrera S, Bujard H.
    Infect Immun; 2006 Feb 16; 74(2):1313-22. PubMed ID: 16428781
    [Abstract] [Full Text] [Related]

  • 27. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
    Mazumdar S, Mukherjee P, Yazdani SS, Jain SK, Mohmmed A, Chauhan VS.
    Infect Immun; 2010 Feb 16; 78(2):872-83. PubMed ID: 19933832
    [Abstract] [Full Text] [Related]

  • 28. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.
    Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW.
    PLoS One; 2008 Jul 30; 3(7):e2830. PubMed ID: 18665258
    [Abstract] [Full Text] [Related]

  • 29. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.
    Carvalho LJ, Alves FA, Bianco C, Oliveira SG, Zanini GM, Soe S, Druilhe P, Theisen M, Muniz JA, Daniel-Ribeiro CT.
    Clin Diagn Lab Immunol; 2005 Feb 30; 12(2):242-8. PubMed ID: 15699417
    [Abstract] [Full Text] [Related]

  • 30. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
    Kumar S, Collins W, Egan A, Yadava A, Garraud O, Blackman MJ, Guevara Patino JA, Diggs C, Kaslow DC.
    Infect Immun; 2000 Apr 30; 68(4):2215-23. PubMed ID: 10722622
    [Abstract] [Full Text] [Related]

  • 31. Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture.
    Jones TR, Gramzinski RA, Aguiar JC, Sim BK, Narum DL, Fuhrmann SR, Kumar S, Obaldia N, Hoffman SL.
    Vaccine; 2002 Feb 22; 20(11-12):1675-80. PubMed ID: 11858878
    [Abstract] [Full Text] [Related]

  • 32. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
    Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA.
    Infect Immun; 2005 Jan 22; 73(1):287-97. PubMed ID: 15618165
    [Abstract] [Full Text] [Related]

  • 33. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK, Mukherjee P, Dhawan S, Pandey AK, Mazumdar S, Gaur D, Jain SK, Chauhan VS.
    Clin Vaccine Immunol; 2014 Jun 22; 21(6):886-97. PubMed ID: 24789797
    [Abstract] [Full Text] [Related]

  • 34. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa.
    John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL, Kazura JW, Crabb BS.
    J Immunol; 2004 Jul 01; 173(1):666-72. PubMed ID: 15210830
    [Abstract] [Full Text] [Related]

  • 35. Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection.
    Makobongo MO, Keegan B, Long CA, Miller LH.
    J Infect Dis; 2006 Mar 01; 193(5):731-40. PubMed ID: 16453270
    [Abstract] [Full Text] [Related]

  • 36. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum.
    Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH.
    Proc Natl Acad Sci U S A; 2002 Jan 08; 99(1):339-44. PubMed ID: 11752405
    [Abstract] [Full Text] [Related]

  • 37. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.
    Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH.
    Infect Immun; 2002 Dec 08; 70(12):6961-7. PubMed ID: 12438375
    [Abstract] [Full Text] [Related]

  • 38. Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19).
    Gozalo A, Lucas C, Cachay M, Wellde BT, Hall T, Bell B, Wood J, Watts D, Wooster M, Lyon JA, Moch JK, Haynes JD, Williams JS, Holland C, Watson E, Kester KE, Kaslow DC, Ballou WR.
    Am J Trop Med Hyg; 1998 Dec 08; 59(6):991-7. PubMed ID: 9886211
    [Abstract] [Full Text] [Related]

  • 39. Failure of a synthetic vaccine to protect Aotus lemurinus against asexual blood stages of Plasmodium falciparum.
    Herrera S, Herrera MA, Corredor A, Rosero F, Clavijo C, Guerrero R.
    Am J Trop Med Hyg; 1992 Nov 08; 47(5):682-90. PubMed ID: 1449209
    [Abstract] [Full Text] [Related]

  • 40. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
    Hisaeda H, Saul A, Reece JJ, Kennedy MC, Long CA, Miller LH, Stowers AW.
    J Infect Dis; 2002 Mar 01; 185(5):657-64. PubMed ID: 11865423
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.